中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

2022
  • 0
Haixia Long, Qingzhu Jia, Liuyang Wang, Wenfeng Fang, Zhongyu Wang, Tao Jiang, Fei Zhou, Zheng Jin, Jiani Huang, Li Zhou, Chunyan Hu, Xinxin Wang, Jin Zhang, Yujie Ba, Yujie Gong, Xianghua Zeng, Dong Zeng, Xingxing Su, Peter B. Alexander, Li Wang, Limei Wang, Yisong Y. Wan, Xiao-Fan Wang, Li Zhang, Qi-Jing Li, Bo Zhu ( 2022)    Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. 
Cancer Cell 40, 674-693, June 13, 2022    DOI:https://doi.org/10.1016/j.ccell.2022.04.018

 

06.14
2022
来源:
关键词:
相关阅读

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer